CN111032045B - 用于治疗血液病症的丙酮酸激酶激活剂 - Google Patents

用于治疗血液病症的丙酮酸激酶激活剂 Download PDF

Info

Publication number
CN111032045B
CN111032045B CN201880053315.9A CN201880053315A CN111032045B CN 111032045 B CN111032045 B CN 111032045B CN 201880053315 A CN201880053315 A CN 201880053315A CN 111032045 B CN111032045 B CN 111032045B
Authority
CN
China
Prior art keywords
methyl
pharmaceutically acceptable
compound
acceptable salt
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880053315.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN111032045A (zh
Inventor
G.奇安切塔
刘涛
A.K.帕德亚纳
隋治华
蔡振伟
崔大为
季竞竞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agios Pharmaceuticals Inc
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Priority to CN202310962497.4A priority Critical patent/CN117186119B/zh
Publication of CN111032045A publication Critical patent/CN111032045A/zh
Application granted granted Critical
Publication of CN111032045B publication Critical patent/CN111032045B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201880053315.9A 2017-08-15 2018-08-15 用于治疗血液病症的丙酮酸激酶激活剂 Active CN111032045B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310962497.4A CN117186119B (zh) 2017-08-15 2018-08-15 用于治疗血液病症的丙酮酸激酶激活剂

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CNPCT/CN2017/097496 2017-08-15
CN2017097496 2017-08-15
US201862673533P 2018-05-18 2018-05-18
US201862673526P 2018-05-18 2018-05-18
US62/673,526 2018-05-18
US62/673,533 2018-05-18
PCT/US2018/000128 WO2019035864A1 (en) 2017-08-15 2018-08-15 PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF BLOOD DISORDERS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310962497.4A Division CN117186119B (zh) 2017-08-15 2018-08-15 用于治疗血液病症的丙酮酸激酶激活剂

Publications (2)

Publication Number Publication Date
CN111032045A CN111032045A (zh) 2020-04-17
CN111032045B true CN111032045B (zh) 2023-08-15

Family

ID=63524352

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201880053315.9A Active CN111032045B (zh) 2017-08-15 2018-08-15 用于治疗血液病症的丙酮酸激酶激活剂
CN202310962497.4A Active CN117186119B (zh) 2017-08-15 2018-08-15 用于治疗血液病症的丙酮酸激酶激活剂
CN201880053325.2A Active CN111032046B (zh) 2017-08-15 2018-08-15 丙酮酸激酶调节剂及其用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202310962497.4A Active CN117186119B (zh) 2017-08-15 2018-08-15 用于治疗血液病症的丙酮酸激酶激活剂
CN201880053325.2A Active CN111032046B (zh) 2017-08-15 2018-08-15 丙酮酸激酶调节剂及其用途

Country Status (34)

Country Link
US (8) US11464775B2 (https=)
EP (4) EP3668881B1 (https=)
JP (5) JP7301040B2 (https=)
KR (3) KR102642408B1 (https=)
CN (3) CN111032045B (https=)
AU (4) AU2018316588B2 (https=)
BR (1) BR112020003254A2 (https=)
CA (1) CA3072455A1 (https=)
CL (1) CL2020000375A1 (https=)
CO (2) CO2020002959A2 (https=)
CR (1) CR20200123A (https=)
CY (1) CY1124953T1 (https=)
DK (2) DK3668513T3 (https=)
EC (1) ECSP20018487A (https=)
ES (3) ES2905100T3 (https=)
FI (1) FI3668512T3 (https=)
HR (2) HRP20220039T1 (https=)
HU (2) HUE061910T2 (https=)
IL (3) IL272599B (https=)
LT (2) LT3668513T (https=)
MD (1) MD3668513T2 (https=)
MX (2) MX2020001833A (https=)
MY (1) MY204421A (https=)
PE (1) PE20200724A1 (https=)
PH (1) PH12020500343B1 (https=)
PL (2) PL3668513T3 (https=)
PT (2) PT3668513T (https=)
RS (2) RS62871B1 (https=)
SG (2) SG11202001262QA (https=)
SI (2) SI3668512T1 (https=)
SM (2) SMT202200023T1 (https=)
TW (3) TWI796353B (https=)
UA (1) UA126292C2 (https=)
WO (3) WO2019035864A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3483164T (lt) 2017-03-20 2020-05-11 Forma Therapeutics, Inc. Pirolpirolo kompozicijos kaip piruvato kinazės (pkr) aktyvatoriai
TWI796353B (zh) * 2017-08-15 2023-03-21 美商阿吉歐斯製藥公司 丙酮酸激酶調節劑及其用途
EP3697354A4 (en) 2017-10-20 2021-06-30 The Regents of The University of Michigan EYE DISEASE COMPOSITIONS AND METHODS
EP3852791B1 (en) 2018-09-19 2024-07-03 Novo Nordisk Health Care AG Activating pyruvate kinase r
EP3853206B1 (en) 2018-09-19 2024-04-10 Novo Nordisk Health Care AG Treating sickle cell disease with a pyruvate kinase r activating compound
BR112021015996A2 (pt) * 2019-02-13 2021-11-09 Agios Pharmaceuticals Inc Derivados de tieno[3,2-b]pirrol[3,2-d]piridazinona e seu uso como derivados de pkm2 para o tratamento de câncer, obesidade e distúrbios relacionados a diabetes
WO2020262419A1 (ja) * 2019-06-26 2020-12-30 日産化学株式会社 電荷輸送性ワニス
HRP20251148T1 (hr) 2019-09-19 2025-11-21 Novo Nordisk Health Care Ag Pripravci koji aktiviraju piruvat-kinazu r (pkr)
EP4185293A4 (en) * 2020-07-21 2025-01-15 The Regents of The University of Michigan COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE
CN112490502B (zh) * 2020-12-04 2022-01-21 广州天赐高新材料股份有限公司 一种电解液及锂二次电池
US11566030B2 (en) 2021-02-08 2023-01-31 Global Blood Therapeutics, Inc. Substituted 2,6-dihydropyrrolo[3,4-c]pyrazoles as pyruvate kinase activators
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
WO2023052783A1 (en) * 2021-09-30 2023-04-06 Sitryx Therapeutics Limited Novel compounds
IL312679A (en) * 2021-11-16 2024-07-01 Agios Pharmaceuticals Inc Compounds for the treatment of anemia associated with MDS and other conditions
CN116159061A (zh) * 2023-03-09 2023-05-26 上海市第十人民医院 丙酮酸激酶m2激活剂在制备预防或治疗心力衰竭的药物中的应用
EP4671102A1 (en) 2023-03-28 2025-12-31 Honda Motor Co., Ltd. METHOD FOR PROVIDING INFORMATION, PROGRAM FOR PROVIDING INFORMATION, STORAGE MEDIA AND INFORMATION PROCESSING APPARATUS
TW202509043A (zh) 2023-05-15 2025-03-01 美商阿吉歐斯製藥公司 ２－（（１ｈ－吡唑－３－基）甲基）－６－（（６－胺基吡啶－２－基）甲基）－４－甲基－４，６－二氫－５ｈ－噻唑基［５＇，４＇：４，５］吡咯并［２，３－ｄ］嗒𠯤－５－酮之結晶形式
KR20260035223A (ko) * 2023-07-05 2026-03-12 아지오스 파마슈티컬스 아이엔씨. 피루브산 키나아제 활성화제의 합성
TW202539675A (zh) 2024-03-27 2025-10-16 美商阿吉歐斯製藥公司 Ｐｋ活化劑在治療鐮狀細胞疾病中之用途
WO2026076363A1 (en) 2024-10-04 2026-04-09 Agios Pharmaceuticals, Inc. Compounds for treating mds-associated anemias and other conditions

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1972629A1 (en) * 2007-03-23 2008-09-24 Mutabilis SA New imidazolo-heteroaryl derivatives with antibacterial properties
CN102159574A (zh) * 2008-07-23 2011-08-17 沃泰克斯药物股份有限公司 三-环吡唑并吡啶激酶抑制剂
CN102448951A (zh) * 2009-04-06 2012-05-09 安吉奥斯医药品有限公司 丙酮酸激酶m2调节剂、治疗组合物和相关使用方法
CN103608016A (zh) * 2011-05-03 2014-02-26 安吉奥斯医药品有限公司 丙酮酸激酶激活剂在治疗中的用途
CN103764147A (zh) * 2011-05-03 2014-04-30 安吉奥斯医药品有限公司 用于治疗的丙酮酸激酶活化剂
CN103930422A (zh) * 2011-07-19 2014-07-16 无限药品股份有限公司 杂环化合物及其用途
CN104822672A (zh) * 2012-11-08 2015-08-05 安吉奥斯医药品有限公司 治疗性化合物和组合物以及其作为pkm2调节剂的用途
CN105121425A (zh) * 2013-03-15 2015-12-02 安吉奥斯医药品有限公司 治疗性化合物和组合物
CN111032046A (zh) * 2017-08-15 2020-04-17 安吉奥斯医药品有限公司 丙酮酸激酶调节剂及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405635A (en) 1979-06-18 1983-09-20 Merrell Dow Pharmaceuticals Inc. 4-Aroylimidazol-2-ones and their use as pharmaceuticals
US4883914A (en) 1987-08-17 1989-11-28 American Cyanamid Company Benzenesulfonyl carboxamide compounds useful as herbicidal agents
CA2380644A1 (en) 1999-07-30 2001-02-08 Basf Aktiengesellschaft 2-pyrazolin-5-ones
CA2381581A1 (en) 1999-09-04 2001-03-15 Astrazeneca Ab Substituted n-phenyl 2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivatives which elevate pyruvate dehydrogenase activity
FR2933983B1 (fr) * 2008-07-15 2010-08-27 Servier Lab Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
EP2334673A1 (en) * 2008-08-29 2011-06-22 Amgen Inc. PYRIDO[3,2-d]PYRIDAZINE-2(1H)-ONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF
WO2010042867A2 (en) 2008-10-09 2010-04-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Activators of human pyruvate kinase
TWI598337B (zh) 2009-06-29 2017-09-11 阿吉歐斯製藥公司 治療化合物及組成物
US20130109672A1 (en) 2010-04-29 2013-05-02 The United States Of America,As Represented By The Secretary, Department Of Health And Human Service Activators of human pyruvate kinase
KR101861883B1 (ko) 2010-12-06 2018-05-28 글락소 그룹 리미티드 Lp-PLA₂에 의해 매개되는 질환 또는 상태의 치료에 사용하기 위한 피리미디논 화합물
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
US9388164B2 (en) * 2011-05-03 2016-07-12 Agios Pharmaceuticals, Inc Methods of using pyruvate kinase activators
WO2012151450A1 (en) 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia
WO2013056153A1 (en) * 2011-10-13 2013-04-18 Kung Charles Activators of pyruvate kinase m2 and methods of treating disease
US9921221B2 (en) 2012-07-26 2018-03-20 Joslin Diabetes Center, Inc. Predicting and treating diabetic complications
WO2014118135A1 (en) * 2013-01-30 2014-08-07 Bayer Pharma Aktiengesellschaft Amidoimidazopyridazines as mknk-1 kinase inhibitors
EP2968323A4 (en) 2013-03-13 2016-12-14 Flatley Discovery Lab PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
AR097543A1 (es) * 2013-09-06 2016-03-23 Lexicon Pharmaceuticals Inc COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
US11465992B2 (en) 2017-07-07 2022-10-11 Inflazome Limited Sulfonamide carboxamide compounds
MX2020001776A (es) 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
AR112475A1 (es) 2017-08-15 2019-10-30 Agios Pharmaceuticals Inc Moduladores de piruvato quinasas y uso de los mismos
US10676485B2 (en) 2017-08-15 2020-06-09 Abbvie Inc. Macrocyclic MCL-1 inhibitors and methods of use
BR112021015996A2 (pt) * 2019-02-13 2021-11-09 Agios Pharmaceuticals Inc Derivados de tieno[3,2-b]pirrol[3,2-d]piridazinona e seu uso como derivados de pkm2 para o tratamento de câncer, obesidade e distúrbios relacionados a diabetes

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1972629A1 (en) * 2007-03-23 2008-09-24 Mutabilis SA New imidazolo-heteroaryl derivatives with antibacterial properties
CN102159574A (zh) * 2008-07-23 2011-08-17 沃泰克斯药物股份有限公司 三-环吡唑并吡啶激酶抑制剂
CN102448951A (zh) * 2009-04-06 2012-05-09 安吉奥斯医药品有限公司 丙酮酸激酶m2调节剂、治疗组合物和相关使用方法
CN103608016A (zh) * 2011-05-03 2014-02-26 安吉奥斯医药品有限公司 丙酮酸激酶激活剂在治疗中的用途
CN103764147A (zh) * 2011-05-03 2014-04-30 安吉奥斯医药品有限公司 用于治疗的丙酮酸激酶活化剂
CN103930422A (zh) * 2011-07-19 2014-07-16 无限药品股份有限公司 杂环化合物及其用途
CN104822672A (zh) * 2012-11-08 2015-08-05 安吉奥斯医药品有限公司 治疗性化合物和组合物以及其作为pkm2调节剂的用途
CN105121425A (zh) * 2013-03-15 2015-12-02 安吉奥斯医药品有限公司 治疗性化合物和组合物
CN111032046A (zh) * 2017-08-15 2020-04-17 安吉奥斯医药品有限公司 丙酮酸激酶调节剂及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase;Jian-kang Jiang等;Bioorganic & Medicinal Chemistry Letters;3387–3393 *

Also Published As

Publication number Publication date
JP2020531443A (ja) 2020-11-05
JP2020531432A (ja) 2020-11-05
US20230226055A1 (en) 2023-07-20
BR112020003262A2 (pt) 2020-09-01
KR20200054200A (ko) 2020-05-19
US11590132B2 (en) 2023-02-28
DK3668512T3 (da) 2023-05-22
WO2019035863A1 (en) 2019-02-21
US20210077490A1 (en) 2021-03-18
JP2023052478A (ja) 2023-04-11
CA3072455A1 (en) 2019-02-21
JP2023027276A (ja) 2023-03-01
IL272597B (en) 2022-06-01
MD3668513T2 (ro) 2022-04-30
SI3668512T1 (sl) 2023-06-30
IL292530A (en) 2022-06-01
TWI796353B (zh) 2023-03-21
KR102642408B1 (ko) 2024-02-28
LT3668512T (lt) 2023-06-12
KR20230127364A (ko) 2023-08-31
CN111032045A (zh) 2020-04-17
EP4026838A1 (en) 2022-07-13
WO2019035863A8 (en) 2019-03-28
PL3668512T3 (pl) 2023-06-19
US11364240B2 (en) 2022-06-21
US20210130371A1 (en) 2021-05-06
MX2020001833A (es) 2020-07-22
US20200206225A1 (en) 2020-07-02
US20250144093A1 (en) 2025-05-08
TW202323258A (zh) 2023-06-16
CY1124953T1 (el) 2023-01-05
US20220233541A1 (en) 2022-07-28
EP3668513B1 (en) 2021-11-10
IL272599B (en) 2022-08-01
CR20200123A (es) 2020-06-29
KR102764124B1 (ko) 2025-02-05
TW201919631A (zh) 2019-06-01
CO2020002961A2 (es) 2020-04-13
AU2018316588A1 (en) 2020-02-20
EP3668881B1 (en) 2023-10-04
HUE057178T2 (hu) 2022-04-28
RU2020110573A3 (https=) 2021-12-24
US20220395503A1 (en) 2022-12-15
PT3668513T (pt) 2022-01-21
TWI823580B (zh) 2023-11-21
WO2019035864A1 (en) 2019-02-21
US11957680B2 (en) 2024-04-16
SG11202001353PA (en) 2020-03-30
LT3668513T (lt) 2022-03-25
RS62871B1 (sr) 2022-02-28
SMT202200023T1 (it) 2022-03-21
IL272597A (en) 2020-03-31
WO2019035865A1 (en) 2019-02-21
SMT202300146T1 (it) 2023-07-20
CN117186119A (zh) 2023-12-08
IL272599A (en) 2020-03-31
HUE061910T2 (hu) 2023-08-28
IL292530B2 (en) 2023-06-01
SG11202001262QA (en) 2020-03-30
PT3668512T (pt) 2023-05-22
ES2905100T3 (es) 2022-04-07
JP7301040B2 (ja) 2023-06-30
EP3668513A1 (en) 2020-06-24
EP3668881A1 (en) 2020-06-24
JP2024147805A (ja) 2024-10-16
FI3668512T3 (fi) 2023-05-12
AU2018316588B2 (en) 2023-02-02
CN111032046B (zh) 2023-09-26
AU2023202772B2 (en) 2024-05-16
RS64221B1 (sr) 2023-06-30
PE20200724A1 (es) 2020-07-21
RU2020110573A (ru) 2021-09-16
AU2018316587B2 (en) 2023-05-11
KR20200054199A (ko) 2020-05-19
US11464775B2 (en) 2022-10-11
HRP20230452T1 (hr) 2023-07-21
ES2966825T3 (es) 2024-04-24
HRP20220039T1 (hr) 2022-04-15
KR102717594B1 (ko) 2024-10-14
CN117186119B (zh) 2026-04-28
US20200207785A1 (en) 2020-07-02
US11040036B2 (en) 2021-06-22
WO2019035865A8 (en) 2019-03-28
AU2024205818A1 (en) 2024-09-05
AU2018316587A1 (en) 2020-02-20
TWI790271B (zh) 2023-01-21
JP7530453B2 (ja) 2024-08-07
CN111032046A (zh) 2020-04-17
JP7275107B2 (ja) 2023-05-17
US11872225B2 (en) 2024-01-16
PH12020500343B1 (en) 2024-02-21
ES2944545T3 (es) 2023-06-22
DK3668513T3 (da) 2022-01-10
SI3668513T1 (sl) 2022-04-29
UA126292C2 (uk) 2022-09-14
MX2020001832A (es) 2020-07-22
BR112020003254A2 (pt) 2020-10-27
WO2019035864A8 (en) 2019-03-28
PL3668513T3 (pl) 2022-03-21
TW201920203A (zh) 2019-06-01
MY204421A (en) 2024-08-28
EP3668512A1 (en) 2020-06-24
EP3668512B1 (en) 2023-02-15
ECSP20018487A (es) 2020-05-29
CO2020002959A2 (es) 2020-04-13
CA3071993A1 (en) 2019-02-21
US12133853B2 (en) 2024-11-05
AU2023202772A1 (en) 2023-05-18
CL2020000375A1 (es) 2020-12-11
PH12020500343A1 (en) 2021-02-08

Similar Documents

Publication Publication Date Title
CN111032045B (zh) 用于治疗血液病症的丙酮酸激酶激活剂
HK40077435A (en) Pyruvate kinase activators for use in treating blood disorders
CA3071993C (en) Thiazolo(5',4':4,5)pyrrolo(2,3-d)pyridazine-5-one derivatives and pharmaceutical compositions thereof useful as pyruvate kinase activators for use in treating blood disorders
HK40030323B (en) Pyruvate kinase activators for use in treating blood disorders
BR112020003262B1 (pt) Composto, composição farmacêutica e usos do referido composto e da referida composição no tratamento de distúrbios do sangue
EA042084B1 (ru) Активаторы пируваткиназы для применения в лечении нарушений со стороны крови

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant